These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18704929)

  • 1. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.
    Carpenter JF; Randolph TW; Jiskoot W; Crommelin DJ; Middaugh CR; Winter G; Fan YX; Kirshner S; Verthelyi D; Kozlowski S; Clouse KA; Swann PG; Rosenberg A; Cherney B
    J Pharm Sci; 2009 Apr; 98(4):1201-5. PubMed ID: 18704929
    [No Abstract]   [Full Text] [Related]  

  • 2. Best practices for managing quality and safety of foreign particles in orally inhaled and nasal drug products, and an evaluation of clinical relevance.
    Blanchard J; Coleman J; Crim C; Dabreu-Hayling C; Fries L; Ghaderi R; Haeberlin B; Malcolmson R; Mittelman S; Nagao L; Saracovan I; Shtohryn L; Snodgrass-Pilla C; Sundahl M; Wolff R
    Pharm Res; 2007 Mar; 24(3):471-9. PubMed ID: 17252189
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of compounding on sterility and stability of drugs.
    Hardee GE
    J Am Vet Med Assoc; 1994 Jul; 205(2):224-5. PubMed ID: 7928582
    [No Abstract]   [Full Text] [Related]  

  • 4. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products.
    Carpenter JF; Randolph TW; Jiskoot W; Crommelin DJ; Middaugh CR; Winter G
    J Pharm Sci; 2010 May; 99(5):2200-8. PubMed ID: 19918982
    [No Abstract]   [Full Text] [Related]  

  • 6. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirtieth report.
    World Health Organ Tech Rep Ser; 1987; 748():1-50. PubMed ID: 3111103
    [No Abstract]   [Full Text] [Related]  

  • 7. On developing a process for conducting extractable-leachable assessment of components used for storage of biopharmaceuticals.
    Wakankar AA; Wang YJ; Canova-Davis E; Ma S; Schmalzing D; Grieco J; Milby T; Reynolds T; Mazzarella K; Hoff E; Gomez S; Martin-Moe S
    J Pharm Sci; 2010 May; 99(5):2209-18. PubMed ID: 20039383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial endotoxin requirements for dry powder inhalants and their excipients: are they critical quality attributes?
    Cundell AM
    PDA J Pharm Sci Technol; 2014; 68(5):386-93. PubMed ID: 25336414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industry perspective on the medical risk of visible particles in injectable drug products.
    Bukofzer S; Ayres J; Chavez A; Devera M; Miller J; Ross D; Shabushnig J; Vargo S; Watson H; Watson R
    PDA J Pharm Sci Technol; 2015; 69(1):123-39. PubMed ID: 25691720
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of poor-quality medicines in the 'developing' world.
    Newton PN; Green MD; Fernández FM
    Trends Pharmacol Sci; 2010 Mar; 31(3):99-101. PubMed ID: 20117849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 14. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin.
    Lippi G; Franchini M; Favaloro EJ
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):1-3. PubMed ID: 20527719
    [No Abstract]   [Full Text] [Related]  

  • 15. Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations.
    Norwood DL; Paskiet D; Ruberto M; Feinberg T; Schroeder A; Poochikian G; Wang Q; Deng TJ; DeGrazio F; Munos MK; Nagao LM
    Pharm Res; 2008 Apr; 25(4):727-39. PubMed ID: 18183477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for field surveys of the quality of medicines: a proposal.
    Newton PN; Lee SJ; Goodman C; Fernández FM; Yeung S; Phanouvong S; Kaur H; Amin AA; Whitty CJ; Kokwaro GO; Lindegårdh N; Lukulay P; White LJ; Day NP; Green MD; White NJ
    PLoS Med; 2009 Mar; 6(3):e52. PubMed ID: 19320538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [How, when and why do the drugs go out of date].
    Lapinjoki S
    Duodecim; 2001; 117(2):187-91. PubMed ID: 12092372
    [No Abstract]   [Full Text] [Related]  

  • 20. Extemporaneously compounded sterile medications: relevance of new United States pharmacopeial standards to pain clinicians.
    Rusho WJ
    J Pain Palliat Care Pharmacother; 2004; 18(4):69-76. PubMed ID: 15760810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.